NHF adds new drugs for four conditions
National Health Fund (NHF) adds new drugs for four conditions - hypertension, vascular disease, psychosis and major depression.
NHF cardholders are to benefit from the addition of new drugs for the treatment of hypertension, vascular disease, psychosis and major depression.
New, for the treatment of hypertension, is Ramlon capsules with the active ingredients Ramipril and Amlodipine, and NHF offers a subsidy of $46.29 per 5mg capsule and $83.73 per 10mg capsule.
Pradax capsules with the active Dabigatran with a subsidy of $87.00 per 75mg capsule and $127.60 per 110mg capsule, as well as Eliquis tablets with the active ingredient Apixaban with a subsidy of $72.48 per 2.5mg tablet and $144.95 per 5mg tablet, along with Xarelto tablets with the active ingredient Rivaroxban with a subsidy of $244.95 per 15mg tablet and $326.60 per 20mg tablet, have all been added for the treatment of vascular disease.
In addition, Invega Sustenna injections with the active ingredient Paliperidone Palmitate for the treatment of psychosis and major depression are now subsidised by NHF. The NHF offers a subsidy of $19,647.75 per 75mg injection, $26,197.00 per 100mg injection and $39,295.50 per 150mg injection.
A complete drug list and subsidies paid by the National Health Fund are available from NHF participating pharmacies, the NHF website or by calling NHF (1-888-NHF-CARE).